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Abstract In RCS rats, the retinal pigment epithelium (RPE) is 
defective in phagocytosis of photoreceptor membranes. We have 
previously shown reduced expression of basic fibroblast growth 
factor (bFGF) in the RPE of 7-10-day-old RCS rats. This study 
using primary RPE cultures from rats of this age demonstrates 
that the phagocytic defect in the mutant RPE can be overcome 
by treatment with bFGF, by a mechanism involving gene 
transcription and that normal RPE phagocytosis, also requiring 
transcription, is blocked by a bFGF neutralizing antibody. The 
combined data point to a role for bFGF in the normal mechanism 
of RPE phagocytosis and the RCS defect. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
In the retina, synchronized phagocytosis of several hundred 
packets of photoreceptor outer segment membranes is a daily 
task of each cell of the retinal pigment epithelium (RPE), 
necessitated by the ongoing renewal and rhythmic shedding 
of disc membranes by the neighboring visual cells [1-3]. The 
Royal College of Surgeons (RCS) rat is a rodent model of 
hereditary photoreceptor degeneration in which an unidenti-
fied genetic defect {rdy) known to be expressed in the R P E 
renders these cells defective in the phagocytic process. As a 
result, membranous debris accumulates in the subretinal space 
from postnatal day 12 (PI2) onward, and the photoreceptors 
degenerate and disappear from the retina between P20 and 
P60, although the mutant R P E cells remain in place for 
many months [4-9]. The phagocytic defect is retained in pri-
mary cultures of R P E cells isolated from 6 to 12-day-old RCS 
rats, following phagocytic challenge with isolated rod outer 
segments (ROS) [10]. Previous studies with the mutant R P E 
cells have determined that this defect is specific to ROS and 
involves impaired ROS ingestion subsequent to binding to the 
cell surfaces [10,11]. It is widely accepted that normal R P E 
phagocytosis is a receptor-mediated process involving a gly-
coprotein interaction but the identity of the cell surface recep-
t o r s ) participating in ROS binding and ingestion is currently 
a subject of ongoing investigation. (For a comprehensive re-
view of literature up to 1994, see [12].) To date, two known 
receptors, i.e. the macrophage mannose receptor [13] and the 
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scavenger receptor CD36 [14], as well as other unknown pro-
teins of R P E plasma membranes [15,16], have been proposed 
as candidates for the ROS receptor. 
Basic F G F (FGF-2) is a widely distributed heparin-binding 
growth factor with a remarkably diverse range of actions crit-
ical in normal development, reproduction, angiogenesis and 
responses of the nervous system to injury [17-23]. Although 
intraocular injection of several different neurotrophic factors 
including b F G F has been shown to protect normal rat photo-
receptors from insults such as light damage [24] and physical 
t rauma [25], only b F G F has been shown to delay the demise 
of the photoreceptors in the RCS model of inherited retinal 
degeneration [26]. We have recently shown that b F G F m R N A 
and protein expression are markedly down-regulated in the 
R P E of RCS rats during the developmental period (P7-P12) 
when expression of the phagocytic defect first occurs in vivo 
[27]. Since the primary genetic defect resides in the R P E in 
this model [7], the present investigation tested whether exoge-
nously added b F G F could also improve the phagocytic capa-
bility of the mutant R P E cells, using an in vitro paradigm. 
Due to the marked phenotypic heterogeneity characteristic of 
rat primary R P E cultures, and profound differences in kinetics 
of phagocytosis by cells of different phenotypes [28], analyses 
described here were performed over cells within the cultures 
having morphology and phagocytic behavior (i.e. synchro-
nous ingestion of multiple ROS per cell) closest to that of 
R P E in vivo. Here we demonstrate (1) that mutant rat R P E 
cells can be stimulated to ingest bound ROS at the same rate 
as normal R P E cells following treatment with b F G F , by a 
mechanism requiring gene transcription and (2) that R O S in-
gestion by normal R P E cells, which is also under transcrip-
tional control, is inhibited by a neutralizing antibody to 
b F G F . This is the first demonstration of reversal of the 
RCS defect by any agent, and of the involvement of b F G F 
in the normal mechanism of R P E phagocytosis. 
2. Materials and methods 
2.1. Primary RPE cultures 
RPE cells were isolated from 7-11-day-old normal (RCS rdy+p+ or 
RCS rdy+) and dystrophic (RCS p+) rats as described [29]. To min-
imize cell spreading and dedifferentiation in vitro [30], RPE cell sheets 
were incompletely dispersed following isolation, and the resultant 
mixture of single cells and epithelial patches was plated at high density 
in a very small volume (3X104 cells in 50 u.1 of medium per well; 
1.5XlO°/cm2) in 8-well glass chamber slides as previously described 
[28], The primary cultures were grown to confluence for 6-9 days in 
minimum essential medium with Earle's salts, MEM (Gibco)+20% 
FBS+antibiotics (500 u.l/well), at which time the pigmented cultures 
were visible as dark spots of uniform diameter ( ~ 5 mm) centered in 
the wells of the chamber slides. 
2.2. Pretreatment with growth factors and inhibitors 
Preliminary experiments, in which bFGF at various concentrations 
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was added at several intervals prior to ROS addition, revealed that 24 
h pretreatment of dystrophic RPE cells with 100-200 ng/ml of this 
growth factor reproducibly resulted in a pronounced acceleration of 
ROS ingestion by the cells, whereas addition of bFGF at the time of 
ROS feeding had much less effect. For all experiments reported here, 
cultures were pretreated with all growth factors for 24 h prior to 
commencement of the phagocytosis assays. For dose-response experi-
ments replicate RCS p + cultures were pretreated with bFGF at con-
centrations of 0, 0.001, 0.01, 0.1, 1.0, 10.0 and 100.0 ng/ml, and fixed 
at either 11 or 19 h after addition of ROS. In other experiments, 
bFGF concentration was 100 ng/ml unless otherwise indicated. The 
selected concentrations of EGF and NGF (100 ng/ml) were based on 
previous demonstrations at this dosage of mitogenic or functional 
responses by cultured RPE cells to mouse or recombinant human 
EGF [31-33] and by rat pheochromocytoma and chromaffin cells to 
mouse NGF [34]. Replicate cultures (8-20/experiment) were pre-
treated in low-serum control medium alone (MEM+5% FBS) or con-
trol medium+bFGF, aFGF, EGF or NGF. Bovine pituitary bFGF 
was obtained from three sources: Collaborative Research (Bedford, 
MA), Sigma (St. Louis, MO) and R&D Systems (Minneapolis, MN). 
Bovine brain aFGF and recombinant human EGF were from Collab-
orative Research; NGF from mouse submaxillary gland was from 
Upstate Biotechnology (Lake Placid, NY). In some experiments, cells 
were pretreated for 24 h, with or without 10 ng/ml bovine bFGF, in 
media containing a goat anti-bFGF antibody (100 (ig/ml) that neu-
tralizes the biological activity of human and bovine bFGF (both re-
agents from R&D Systems). In experiments to investigate transcrip-
tional control of phagocytosis, actinomycin D (Act D; Sigma, 1 |Xg/ 
ml) was included in the culture medium 3 h prior to ROS addition. At 
the end of the 19 h phagocytosis assay, viability of the Act D-treated 
cells was assessed by Trypan blue exclusion, and by ability of the 
cultures to thrive for several days after removal of Act D. 
2.3. Phagocytosis assays 
Except as noted, all steps of our double fluorescent vital assay of 
ROS phagocytosis were performed as described in detail elsewhere 
[35]. The assay takes advantage of phagosome-lysosome fusion to 
enable ROS bound to the cell surface to be distinguished from inter-
nalized ROS. Briefly, 24^18 h prior to ROS addition, primary lyso-
somes in the RPE cells are vitally stained with sulforhodamine (SR), a 
red fluorescent lysosomotropic dye. The phagocytic particles, i.e. rat 
ROS are isolated from retinas of adult Long Evans rats by homoge-
nization followed by sucrose density gradient centrifugation, and are 
then fluorescently stained with fluorescein isothiocyanate (FITC). The 
FITC-ROS are fed to the SR-stained RPE cultures. Following inges-
tion, phagosome-lysosome fusion rapidly occurs and SR is transferred 
to the resultant phagolysosomes. Thus by fluorescence microscopy, 
the internalized ROS in phagolysosomes appear double-labeled with 
FITC and SR, whereas ROS remaining bound to the cell surfaces are 
labeled only with FITC [35]. In all experiments described here, 24 h 
before addition of ROS, primary RPE cultures were switched to low-
serum control medium (MEM+5% FBS) containing 40 ng/ml SR 
(Molecular Probes, Eugene, OR) along with added bFGF or other 
growth factors in some wells. Growth factors were added as necessary 
to all subsequent changes of media until the time of fixation. On the 
day of the assay, isolated rat ROS were freshly prepared and FITC 
stained as described [35]. Meanwhile, SR-containing media were re-
placed with several changes of fresh SR-free media, MEM+5% FBS 
(450 ul/well). Cells were allowed to condition the final change of 
medium for 3 h before FITC-ROS, suspended in MEM+5% FBS, 
were added to each well (108 ROS/ml; 50 ul/well). Cultures were 
incubated with FITC-ROS for durations of 3-19 h; at 2 h intervals, 
ROS-containing media were rapidly removed by aspiration, cultures 
were washed several times with fresh media, then fixed in buffered 2% 
paraformaldehyde for quantitation of bound and ingested ROS. Ef-
fects of pretreatment with growth factors, anti-bFGF antibody and 
actinomycin D were compared with control (MEM+5% FBS) in 16 
separate experiments (9 dystrophic, 7 normal), using replicate cultures 
fixed at 2-5 different time points after ROS addition. Using a Zeiss 
Photomicroscope III equipped as previously described [28], culture 
morphology was assessed by phase contrast microscopy and quanti-
tation of bound and ingested ROS was performed by fluorescence 
microscopy using a high resolution 25 X water immersion objective. 
Counts were made over central regions of confluent cultures, in fields 
with comparable morphology, comprised of patches of heavily pig-
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mented, unspread cells close in size and appearance to RPE in vivo 
(previously defined as 'subtype 1' RPE [28]), or of a mixture of RPE 
subtype 1 and immediately adjacent unspread daughter cells (RPE sub-
type 2), arranged in a compact monolayer with cobblestone morphol-
ogy. Bound and ingested ROS were counted at 40 X using a 0.5 X 0.5 cm 
ocular grid over 10-20 such fields/culture (field size: 0.021 mm2; RPE 
density: 25-30 cells/field). For each treatment, mean counts per field 
were compared with those of the untreated replicate culture. Statistical 
significance of differences was assessed among treatments by analysis of 
variance, and by Student's ?-test for paired data. 
Representative untreated and bFGF-treated cultures, showing 
mainly bound or ingested ROS respectively, as assessed by the double 
fluorescent technique, were also examined by fluorescence microscopy 
using a Noran scanning laser confocal microscope. Sixty serial optical 
sections, 0.3 um apart, were obtained through typical fields of cells 
and the images were then processed using the Noran InterVision 3-D 
analysis software program, to produce vertical ('Z') sections through 
the thickness of the cultures. 
3. Results 
We have recently demonstrated in primary R P E cultures 
from normal rats that whereas highly spread (subtype 3) 
R P E cells rapidly bind and continually ingest R O S after short 
(30 min to 3 h) incubation times in M E M + 5 % FBS, R P E 
subtypes 1 and 2, with unspread cuboidal phenotype, bind 
very few ROS during 3-9 h incubations, then exhibit avid 
binding and synchronous ingestion of multiple R O S per cell 
between 9 and 11 h [28]. As also described previously, in this 
study R P E subtype 1 and 2 cells from dystrophic rats dem-
onstrated steadily increasing total ROS counts during the first 
11 h of incubation with ROS, with most of this increase rep-
resenting ongoing R O S binding with minimal ingestion (Fig. 
1A). Between 11 and 19 h, the total R O S counts/field (boun-
d+ingested) declined slightly and during this interval, the 
numbers of ingested ROS/field rose steadily, accounting for 
15.2%, 34.9% and 51.4% of total ROS respectively, after 11, 
15 and 19 h incubations (Fig. 1A). Replicate cultures from 
these experiments, pretreated for 24 h with b F G F and fixed at 
the same times after ROS addition, revealed an apparent re-
duction in R O S binding and a profound increase in R O S 
ingestion, starting at 5 h (Fig. IB). At the 7 h timepoint, 
mean numbers of ingested ROS/field were more than 13-fold 
higher than control, and the percentage of ingested ROS was 
increased to 53.6, compared with only 3.0 in the control well. 
At 11 h, numbers of ingested ROS in the bFGF-t rea ted cul-
tures were 4-fold higher than control, and 91.8% of the R O S 
were ingested, vs. 15.2% in control. By 15 h, ingestion was 
approximately double that of control ; thus at this time the 
cells in the control cultures appeared to be catching up. At 19 
h, counts of ingested R O S in control cultures continued to 
increase; however, at that time, ingestion in the bFGF- t rea ted 
cells was 3.6 X that of control (Fig. 1A,B). Thus at all times 
after 3 h, R O S ingestion in the bFGF-pre t rea ted wells was 
clearly ahead of replicate untreated controls (P < 0.005). Fig. 
1C-E shows fluorescence micrographs from a phagocytosis 
assay, showing typical results obtained with replicate un-
treated and bFGF-pre t rea ted mutan t R P E cultures (see 
legend for details). The bFGF-media ted ingestion of the 
bound R O S was also confirmed by an independent method, 
i.e. scanning laser confocal microscopy (see below). 
Dose-response assays were performed in replicate cultures 
pretreated with M E M + 5 % FBS alone, or with the addition of 
b F G F (0.1-100 ng/ml), and the results revealed a clearcut 
dose-response effect (Fig. 2). In the untreated controls, counts 
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Fig. 1. Enhanced phagocytosis of isolated rat ROS by bFGF-pretreated RPE cells from mutant RCS rats. A,B: Replicate cultures were pre-
treated 24 h prior to ROS addition either with low-serum medium (MEM+5% FBS) alone as control (A) or with added bFGF, 100 ng/ml (B). 
All cultures were fed with FITC-stained ROS at / = 0, then pairs of replicate control and bFGF-pretreated cultures were washed and fixed at 
the indicated times thereafter. Bound and ingested ROS were counted by fluorescence microscopy over patches of RPE cells with phenotype 
closely resembling RPE in situ. Ingestion of ROS in the bFGF pretreated cells is significantly enhanced over untreated controls starting at 5 h 
after ROS addition (P< 0.005). Data are combined from two separate experiments; counts are means from 10-20 fields per timepoint; error 
bars represent ± 1 SD. Percentages in parentheses refer to percent of total ROS (bound+ingested) that are ingested. C-E: Typical fluorescence 
microscopic data showing bFGF-mediated rescue of phagocytosis in dystrophic RPE cells. C: Untreated (MEM) mutant culture, fixed 11 h 
after feeding FITC-ROS and viewed with a non-selective FITC filter set as described [35]. D,E: Replicate cultures from this experiment, pre-
treated with bFGF and fixed 11 and 19 h, respectively, after FITC-ROS addition, viewed as in (C). In the fixed cultures, FITC-ROS remaining 
bound to the cell surface appear yellow-green (arrowheads in C), whereas ingested ROS, double stained with FITC+SR, appear as bright yel-
low spots (arrows in D,E), primarily in focus at the level of the cell nuclei (N). Bar = 37 |xm. 
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about 40% above control levels both at 11 and 19 h, and 
counts of ingested ROS were increased approximately 250% 
above control at both times (Fig. 2A,B; 1.0 ng/ml). Thus 
bFGF at a concentration of 1 ng/ml seemed to both enhance 
ROS binding and accelerate ingestion of the bound ROS, 
since ingestion must be preceded by binding. In the cultures 
pretreated with 10 ng/ml bFGF, total ROS/field were slightly 
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Fig. 3. Biphasic effect of bFGF pretreatment on ROS phagocytosis by cultured RPE from normal (RCS congenic control) rats. A,B: Normal 
RPE cultures were pretreated for 24 h with control medium alone or with added bFGF (100 ng/ml), and assayed for phagocytic ability at vari-
ous intervals after ROS challenge, as described for the mutant RCS RPE cultures. A: Normal subtype 1 and 2 RPE cells, pretreated only with 
control medium, are slow to bind ROS during the first 9 h of ROS incubation, binding ROS in clusters on the cell surface, then synchronously 
ingesting multiple bound ROS within the next 2 h. A second ingestion peak is observed at 19 h. B: bFGF-pretreated normal cultures show ap-
parent reduced binding but accelerated ingestion during the first 9 h of incubation, with no subsequent effect on total numbers of ingested 
ROS after 11 or more hours. 
higher than control levels at both 11 and 19 h, and the percent 
ingested ROS increased from 37.3% at 11 h to 61.9% at 19 h 
(compare Fig. 2A,B; 10 ng/ml). At the highest bFGF concen-
tration tested, over 80% of the ROS were ingested at 11 h, 
compared with 9% for untreated replicate cultures (Fig. 2A) 
and at 19 h, total ROS per field were double that of control, 
and 100%o of the ROS, vs. 18% in the control, were ingested 
(Fig. 2B). The results with 100 ng/ml bFGF, showing 80-
100% ingestion at both times thus suggested that these cells 
had undergone a second round of binding after the 11 h time-
point, followed by a second ingestion peak observed at 19 h. 
The distribution of bound and ingested ROS in cultures 
from the dose-response assays is shown in Fig. 2C. In the 
untreated cultures, the surface-bound ROS became increas-
ingly clumped and patchy between 11 and 19 h, but most of 
the clustered ROS remained uningested (Fig. 2C, 0 ng/ml; 
compare at 11 and 19 h). In the cultures treated with 1 ng/ 
ml bFGF, enhanced binding and clumping of the bound ROS, 
relative to the untreated control, was observed at 11 h (Fig. 
2C, upper panel; compare bound ROS, indicated by arrow-
heads, at 0 and 1.0 ng/ml). After 19 h, significantly increased 
ingestion was evident in these cultures (Fig. 2C, lower panel; 
compare 0 and 1.0 ng/ml, ingested ROS indicated by arrow). 
In cultures pretreated with 100 ng/ml bFGF, avid ingestion 
was evident in many cells at 11 h, and a strikingly high level 
of ingestion was observed after 19 h (Fig. 2C, 100 ng/ml, 11 
and 19 h). Thus from the observed patterns of ROS distribu-
tion in these cultures, it appeared that the normal sequence of 
events leading to ingestion, i.e. ROS binding, followed by 
ROS clustering and finally by ingestion, was progressively 
accelerated in mutant cultures treated with increasing concen-
trations of bFGF. To provide independent evidence that ROS 
ingestion was indeed enhanced in the bFGF-treated wells, 
representative replicate cultures from this experiment were 
also analyzed by confocal microscopy to produce vertical 
('Z') sections through typical fields, as described in Section 
Fig. 2. Dose-dependent rescue of ROS phagocytosis by bFGF in mutant rat RPE cells. A,B: Quantitation of bound and ingested ROS in 
phagocytosis assays. Replicate cultures were pretreated for 24 h with MEM+5% FBS alone, or with the addition of one of several concentra-
tions of bFGF, then fixed at 11 h (A) or 19 h (B) after continuous ROS feeding. With increasing concentrations of bFGF, mutant RPE cells 
acquire the ability to ingest bound ROS. Symbols denote significance of differences in ingestion levels between bFGF-pretreated and untreated 
controls (•) P<0.05; (••) P< 0.005. C: Appearance of ROS-fed mutant cultures from a dose-response experiment. Upper and lower panels 
on the left are phase contrast images showing culture morphology after fixation. Panels on the right are fluorescence micrographs showing dis-
tribution of bound and ingested ROS in replicate cultures pretreated with the indicated concentrations of bFGF and fixed at either 11 h (upper 
panels) or 19 h (lower panels) after addition of isolated FITC-stained rat ROS. In black and white photographs of the double fluorescent phag-
ocytosis assay, individual bound FITC-ROS, in focus at the level of the cell surfaces, appear as weakly fluorescent round masses, often grouped 
in clusters (arrowheads). Ingested ROS are distinguishable as smaller bright fluorescent spots within the cell bodies, in focus at the level of the 
cell nuclei, N (arrows). Insets in the upper panels show bound and ingested ROS in vertical sections, reconstructed by 3-D analysis of serial op-
tical sections through the corresponding cultures, obtained by scanning laser confocal microscopy. In cultures pretreated with increasing concen-
trations of bFGF, the mutant cells compact and subsequently ingest the clusters of bound ROS, the great majority of which in untreated cul-
tures remain bound to the cell surfaces due to the ingestion defect. The phase contrast image in the upper panel is of the field shown in the 
untreated control culture (0 ng/ml bFGF); lower panel phase image is of the field of highly phagocytic cells on the right, treated with 100 ng/ 
ml bFGF. Bar = 42 urn. 
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Fig. 4. Comparison of ROS ingestion rates in mutant and normal rat RPE cells pretreated with bFGF and other growth factors. A,B: Repli-
cate RCS dystrophic (A) and normal congenic control (B) RPE cultures from experiments shown in Figs. 1 and 3 were pretreated for 24 h 
with control medium alone, or with added bFGF, aFGF, EGF or NGF (all at 100 ng/ml), and assayed for phagocytic ability at 2 h intervals 
from 3 to 19 h after ROS challenge. A: Representative results, shown here at the 7 and 11 h timepoints, show that bFGF, and to a lesser ex-
tent aFGF, but not other growth factors are effective in accelerating ROS ingestion in the mutant cells. B: None of the tested growth factors 
significantly alters total numbers of ROS ingested by normal cells, except as previously noted for bFGF in Fig. 3B. 
2. This analysis confirmed that in untreated controls, the ma-
jority of the ROS were on the cell surfaces whereas following 
bFGF treatment they were internalized (Fig. 2C, insets, 0 and 
100 ng/ml). 
To examine the effect of bFGF pretreatment on normal 
RPE cells, similar experiments were conducted in which phag-
ocytosis was assessed from 3-19 h after ROS addition in 
replicate cultures pretreated in MEM+5% FBS with or with-
out 100 ng/ml bFGF. As previously described for subtype 1 
and 2 normal RPE cells [28], few ROS were bound or ingested 
after brief (3 h) incubations, but after prolonged (7-11 h) 
incubations, multiple ROS were bound in large clusters on 
the surfaces of these cells, and then ingested en masse during 
the subsequent 2 h (Fig. 3A). With further incubation, i.e. 
from 13-17 h, the total numbers of ROS per field declined 
somewhat, and at all times after 9 h, over 90% of the total 
ROS were ingested. At 19 h, a second peak of ingestion oc-
curred (Fig. 3A). Comparison of bFGF-pretreated normal 
cultures with replicate untreated controls fixed 3 and 9 h after 
ROS addition revealed decreased numbers of bound ROS and 
increased numbers of ingested ROS at both times (compare 
Fig. 3A,B). At the 9 h timepoint, the decrease in bound ROS 
was more than 10- fold, and the increase in ingested ROS was 
6.5 X higher than control (P< 0.005). Thus in the normal 
cells, bFGF pretreatment seemed to reduce the time spent 
by ROS on the cell surfaces, and to hence accelerate the 
ROS ingestion rate during the 3-9 h interval. However, at 
the 11 h point, and at all times thereafter, numbers of bound 
Fig. 5. Inhibition of mgestion in normal RPE cells by a neutralizing anti-bFGF antibody. Fluorescence micrographs of replicate normal RPE 
cultures fixed 11 h after ROS feeding. Image in (A) shows typical ingestion (arrow) in an untreated culture (MEM). In the replicate culture 
pretreated with an anti-bFGF neutralizing antibody (Ab) shown in (B), most ROS remain in clusters on the cell surfaces (arrowheads), and in-
gestion is markedly inhibited. Bar = 37 urn. 
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Fig. 6. Transcriptional control of bFGF-mediated rescue of ROS 
phagocytosis in mutant RPE cells. A,B: Replicate mutant RPE cul-
tures were pretreated with MEM+5% FBS alone (control, MEM) or 
with addition of bFGF for 24 h prior to addition of ROS (bFGF). 
Three hours prior to ROS addition, actinomycin D (1 ug/ml) was 
added to half of the cultures receiving each pretreatment (Act D, 
bFGF+Act D). All cultures were fixed after a 19 h ROS incubation. 
Avid ingestion of surface bound ROS is observed in the bFGF-pre-
treated cells (bFGF), whereas ROS remain bound in clumps on the 
cell surfaces in cultures receiving bFGF and Act D, as in untreated 
controls. Bar = 40 am. 
and ingested ROS were essentially identical in untreated and 
bFGF-treated replicate cultures (Fig. 3A,B). Thus the initially 
accelerated ingestion rate did not appear to significantly alter 
the overall numbers of ROS that bound, nor the percent in-
gestion at the 11 or 19 h peaks. When the data from compar-
ably treated normal and dystrophic cultures were compared, it 
was seen that ingestion rates of bFGF-pretreated normal or 
dystrophic cells were not significantly different except at the 
3 h timepoint (compare Figs. 1 and 3). Thus it appeared that 
following bFGF pretreatment, dystrophic RPE cells acquired 
the ability to ingest bound ROS at the same rate as normal 
RPE cells with the same phenotype. 
In replicate cultures from the above experiments pretreated 
with EGF, NGF or aFGF and fixed concurrently, patterns of 
ROS binding and ingestion were analyzed at all timepoints; 
quantitative data from several representative incubation times 
are shown in Fig. 4A. In the dystrophic cultures, at no time 
was ingestion increased over untreated control levels in cells 
pretreated with EGF or NGF. As shown above in Fig. 1, 
ingestion was consistently increased in the bFGF-pretreated 
wells starting at 5 h (typical data from 7 and 11 h timepoints 
shown in Fig. 4A). In cultures pretreated with aFGF, a slight 
ingestion increase was seen beginning at 7 h, and this effect 
was pronounced in cultures fixed from 11 h onward (Fig. 4A). 
Thus ROS ingestion was enhanced in dystrophic RPE cells by 
the related peptide growth factors bFGF and aFGF (FGF-2, 
FGF-1), but not by EFG and NGF. Replicate cultures from 
the experiments described above using normal RPE cells were 
also assayed from 3-19 h after ROS addition, following pre-
treatment with bFGF, aFGF, EGF or NGF. Except as noted 
above for bFGF during 3-9 h incubations, no significant dif-
ferences in ingestion rates were observed with any of these 
pretreatments (Fig. 4B). 
The bFGF-mediated reversal of the ingestion defect in mu-
tant RPE cells, previously shown to be deficient in bFGF [27], 
as well as the bFGF-mediated acceleration of ROS ingestion 
in the normal cells, suggested that endogenous bFGF might 
be involved in the mechanism of phagocytosis by RPE cells. 
An antibody known to neutralize the biological activity of 
bFGF (Ab) was used to directly test this hypothesis. Normal 
RPE cells were pretreated in medium alone (MEM) or 
MEM+Ab, then tested for their phagocytic ability. In cultures 
fixed 11 h after ROS feeding, normal levels of ingestion, i.e. 
160 ±20 ingested ROS/field, were observed in the untreated 
controls, but strikingly, ingestion was reduced to less than 
10% of control, i.e. 15 ± 3.2, in cells pretreated with the neu-
tralizing Ab. Fluorescence micrographs from this experiment 
are shown in Fig. 5. Typical for untreated normal cells, very 
few ROS remained bound to the cell surfaces after 11 h, and 
the cell bodies were filled with ingested ROS (Fig. 5A). In 
sharp contrast, in the replicate cultures pretreated with the 
Ab, large clusters of ROS remained bound to the cell surfaces, 
apparently unable to be internalized (Fig. 5B). This result 
clearly indicated the need for endogenous bFGF of the nor-
mal cells to be functional, in order for ROS ingestion to take 
place. In parallel experiments conducted with dystrophic RPE 
cells, as expected, the bFGF-mediated enhancement of phag-
ocytosis was blocked in cultures pretreated with both 
bFGF+Ab, but there was no effect on these ingestion-deficient 
cultures pretreated with Ab alone (data not shown). 
Finally, experiments were performed to test whether the 
FGF-mediated phagocytic rescue effect was under transcrip-
tional control. In mutant cultures pretreated with control me-
dium alone (MEM+5% FBS), as expected, the great majority 
of the ROS remained bound in clumps on the mutant cell 
surfaces after a 19 h incubation with ROS (Fig. 6A, MEM), 
and the counts revealed only 10%> ingestion at this time (Fig. 
6B; MEM). In replicate wells pretreated with bFGF, ROS 
ingestion was rescued (Fig. 6A, bFGF) with counts of in-
gested ROS 10-fold greater than control, and ingestion levels 
at nearly 100% (Fig. 6B; bFGF). In MEM-only pretreated 
replicate wells to which Act D was added 3 h prior to ROS 
addition, ingestion was reduced very slightly, but ROS bind-
ing was not significantly affected by Act D addition (Fig. 6B; 
Act D). Thus ROS binding by the dystrophic cells apparently 
was not dependent upon new transcripts synthesized during 
the 3 h period prior to ROS addition or during the course of 
the assay. In contrast, in replicate cultures pretreated with 
both bFGF and Act D, ingestion was at very low levels 
(6.7% of total ROS), and ROS binding was increased 37% 
above control levels (Fig. 6A,B). Again, ROS binding was 
not reduced by Act D, but the bFGF-induced ability to ingest 
ROS was completely abolished, clearly indicating that the 
rescue of ROS ingestion was dependent upon gene transcrip-
tion ongoing in the bFGF-pretreated, but not untreated mu-
tant cells. Similarly, data from studies with MEM-only and 
bFGF-pretreated normal RPE cultures showed that ingestion 
of bound ROS, but not ROS binding itself, was inhibited by 
treatment with Act D 3 h prior to ROS addition (data not 
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shown). Viability of the cells was not affected by Act D treat-
ment in either dystrophic or normal cultures. 
4. Discussion 
The results of this study demonstrate that 24 h of pretreat-
ment with bFGF enabled RCS dystrophic RPE cells with 
subtype 1 and 2 morphology [28] to ingest as many ROS as 
their normal counterparts (e.g. about 150 and 300 ROS/field 
respectively, after 11 and 19 h incubations). Calculated on the 
basis of 25 cells/field, this represents an average of 6 and 12 
ingested ROS/cell, respectively, at these two times, although 
some cells were seen to ingest many more ROS than this 
average figure. Thus exogenous bFGF enabled the mutant 
cells to overcome the ROS ingestion defect, apparent in un-
treated replicate cultures, which ingested only 1.6 and 3.2 
ROS/cell at the same fixation times, despite comparable levels 
of total ROS. The apparent equalizing effect of bFGF on 
phagocytosis by normal and dystrophic cells was not attrib-
utable however to reduced phagocytosis by the bFGF-pre-
treated normal cultures, since ingestion rates by normal sub-
type 1 and 2 RPE cells at the 11 and 19 h ingestion peaks were 
not significantly different between untreated and bFGF-pre-
treated replicate normal cultures (Figs. 1 and 3). To our 
knowledge, the data presented here provide the first demon-
stration of any agent that can reverse the phagocytic defect 
expressed in vitro in RCS rat RPE cells with type 1 and 2 
phenotype, most closely resembling RPE in situ. Previously, a 
modest increase in ROS ingestion was reported to occur fol-
lowing carbachol treatment of cultured dystrophic RPE cells 
of unspecified morphology, after incubating the cells with 
ROS for 30 min [36]. However, the overall levels of phagocy-
tosis were very low in those experiments, and the ameliorating 
effect could not be reproduced in another laboratory [37]. 
There has also been a recent report that bFGF pretreatment 
had no effect on phagocytosis by cultured RCS RPE cells 
(shown to have cuboidal phenotype resembling our subtype 
1 and 2 cells), after a 1 h incubation with ROS in media 
containing 1% FBS [38]. But in that study as well, baseline 
levels of ROS binding and ingestion, relative to those demon-
strated here, were quite low, i.e. 1000 ROS per well containing 
30000 cells, which averages only 0.03 bound ROS/cell. Under 
such conditions, the effect of bFGF reported here would not 
have been observed. Indeed, in cells with this phenotype, we 
have found very low levels of phagocytosis even after ROS 
incubations of 3-7 h, followed by avid binding and ingestion 
after 9-11 h [28]. This response is in marked contrast to that 
of highly spread (subtype 3 cells) in the same cultures, which 
bind and rapidly ingest ROS shortly after exposure to them. 
The important relationship between RPE phenotype in vitro 
and rates of ROS binding and ingestion has been addressed 
only recently in the RPE phagocytosis literature [28], so that 
in many previous studies, the RPE cell morphology was usu-
ally not shown or described, and ROS incubations were car-
ried out using short intervals (30 min to 3 h) most suitable for 
study of spread RPE cells in lower density cultures. 
The results showed that bFGF from three different sources, 
as well as aFGF, were able to ameliorate the ROS ingestion 
defect in the mutant cells whereas EGF and NGF, tested on 
replicate cultures, did not. Basic and acidic FGF are heparin-
binding peptide growth factors, known to bind with different 
affinity to the same FGF receptors [22]. Expression of FGF 
receptors on cultured normal and dystrophic rat RPE cells has 
been previously reported [39]. Cultured RPE cells are also 
known to respond to, and possess receptors for EGF [31-
33] and NGF [40]. The data shown here are consistent with 
the rescue effect in the mutant cells having been mediated via 
FGF receptors on the cultured RPE cells. However the iden-
tity of the cell surface receptor(s) initiating ROS binding and 
ingestion in normal and bFGF-treated dystrophic RPE cells is 
still an essential, but missing piece of the puzzle. 
From our various studies with bFGF, evidence is gathering 
in support of the hypothesis that this factor may play a cen-
tral role in the mechanism of normal RPE phagocytosis and 
of the RCS phagocytic defect. First, we have recently demon-
strated that in vivo, and in freshly isolated RPE sheets, bFGF 
mRNA and protein expression are markedly reduced in the 
RPE of neonatal RCS rats at the time when the phagocytic 
defect first appears in vivo [27]. Second, we show here that 
bFGF has a rescue effect on the phagocytosis-defective mu-
tant RPE cells in culture. Third, the data from the bFGF-
pretreated normal cells, showing accelerated ingestion rates 
after both 3 and 9 h incubations (Fig. 3), provided the first 
clue that bFGF might be involved in this process in normal 
RPE cells. This in turn led to more direct support for this 
hypothesis, i.e. the demonstration that ingestion in normal 
RPE cells is blocked with a neutralizing antibody to bFGF 
(Fig. 5). Basic FGF is also known to be expressed by 'pro-
fessional' phagocytic cell types such as macrophages [41,42]; 
however, despite the large body of knowledge regarding spe-
cific receptors and intracellular pathways utilized during phag-
ocytosis of various particles by these cells, the possible in-
volvement of bFGF in their phagocytic mechanism has 
rarely been considered. Interestingly, there is recent evidence 
of bFGF up-regulation prior to induction of another special-
ized type of phagocytosis in the nervous system, i.e. ingestion 
of the fragmented myelin sheath by Schwann cells during 
Wallerian degeneration. Acquisition of phagocytic properties 
by this cell type is proposed to involve c-fos induced activa-
tion of bFGF and several other downstream genes [43]. 
The data from the experiments with Act D provide the first 
evidence that ingestion of bound ROS in both normal and 
bFGF-rescued dystrophic RPE cells requires ongoing gene 
transcription. It is possible that bFGF itself may be up-regu-
lated in normal RPE cells following binding of ROS to their 
cell surface receptors, with subsequent bFGF-mediated induc-
tion of downstream transcripts required for ingestion. If so, 
then the application of exogenous bFGF to normal RPE cells 
might have had the effect of eliminating the delay required for 
bFGF induction, thereby enabling extracellular processing 
and ingestion to begin more rapidly after ROS binding. In 
the dystrophic cells, the 'rescue transcripts' clearly were in-
duced by the bFGF treatment, since untreated replicate cul-
tures were unable to ingest the bound ROS. At present, there 
is no information regarding FGF-mediated induction of any 
specific gene product in RPE cells. However, a number of 
genes known to be expressed in RPE have been shown to 
be induced by bFGF in other cell types; these include tyrosine 
hydroxlyase [44-47], FGF receptor type 1 [39,45,47], integrin 
receptors [48-50], urokinase-type plasminogen activator recep-
tor [51,52], matrix metalloproteinases [53-55] and metallothio-
nein [52,56]. In pursuing the molecular mechanisms of normal 
RPE phagocytosis and of the bFGF-induced rescue effect, it 
will be of interest to test for possible induction of bFGF, as 
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well as the above transcripts and those of postulated R O S 
receptors [13-16], in normal and bFGF- t rea ted dystrophic 
R P E cells. This task should be made easier with the availabil-
ity of immortal R P E cell lines from congenic control and 
mutan t R C S rats [57], since R P E cell lines are more suitable 
than primary cultures for studies of gene expression during 
phagocytosis [28]. 
It will also be important to determine if the bFGF-media ted 
rescue in culture is relevant to the R P E phagocytic defect in 
vivo. In a previous study in which b F G F was injected into 
R C S rat eyes on P23, neurotrophic effects on photoreceptors 
were observed 1-2 months later, without apparent improve-
ment in R P E phagocytosis [26]. By P23 in this mutant , how-
ever, there is already substantial accumulation of membra-
nous debris in the subretinal space [4] which might interfere 
with delivery of b F G F to the RPE. Based on the finding that 
b F G F m R N A and protein are down-regulated in the mutan t 
R P E in vivo during the developmental period (P7-P12) when 
normal phagocytosis is established and the R C S defect begins 
[27], and on observations consistent with improved phagocy-
tosis in vivo, following b F G F injections into eyes of R C S rat 
pups [58], further studies are in progress to pursue the mech-
anism of the bFGF-media ted rescue of phagocytosis in vitro 
and in vivo, in R P E cells from neonatal R C S rats. 
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